Solana is hosting its annual Breakpoint 2026 conference from November 15 to 17 in London, focusing on themes like stablecoins, tokenized assets, and AI-driven crypto activity. Ahead of the event, the network's current status shows a cooling market with a 22% drop in SOL price over 30 days and a 16% decline in total value locked (TVL). Key projects concentrate heavily on staking and lending, with a few large teams dominating the ecosystem. The conference's announcements and market reactions remain unknown until after the event, making current data a snapshot rather than a forecast.
Solana ecosystem ahead of Breakpoint 2026 offers context for crypto market conditions. For readers following major cryptocurrencies on Pluang, as of Nov 13, 2026 17:21 WIB, 12 out of 50 major cryptocurrencies rose while 37 fell. Notable movers include FIL at Rp13.282 with a 1-day change of -3.12%, MANA at Rp1.228 down 2.77%, and LUNC at Rp0.681 with a 1-day change of -2.65%.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
